🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. Class I or III Antiarrhythmic Medications

    Rhythm Pharmaceuticals Netherlands B.V.

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  2. Clazakizumab

    CSL Behring GmbH

    Antibody-mediated Rejection

    phase 3 mab terminated

    1 trial

  3. Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substances for patients with chronic stable plaque poriasis

    Alphapharm Pty Ltd

    Chronic stable plaque psoriasis

    phase 3 other active

    1 trial

  4. Cloxacilin

    Lxo Ireland Designated Activity Company

    Staphylococcus

    phase 3 small molecule terminated

    1 trial

  5. Coagulation Factor VIIa (Recombinant)

    Laboratoire HRA Pharma

    Hemophilia

    phase 3 mab terminated

    1 trial

  6. Coenzyme Q10 and Lisinopril

    United Therapeutics Europe Ltd

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    1 trial

  7. Cold Stored Platelets

    United Therapeutics Europe Ltd

    Acute Blood Loss

    phase 3 mab completed

    1 trial

  8. Combipress 150 mg/5 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 150 mg/10 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 300 mg/10 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 300 mg/5 mg επικαλυμμένα με λεπτό υμένιο δισκία

    Lacuna Pharma Pty Ltd

    Arterial Hypertension

    phase 3 small molecule active

    1 trial

  9. Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  10. Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Promyelocytic Leukaemia

    phase 3 small molecule active

    1 trial

  11. Concurrent chemotherapy

    Disc Medicine

    Uterine Cervical Neoplasms

    phase 3 small molecule active

    1 trial

  12. Conivaptan hydrochloride

    CUMBERLAND PHARMACEUTICALS INC

    Hyponatremia

    phase 3 small molecule terminated

    1 trial

  13. Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, Conjunctival Provocation Test Olea europaea LETI 30 HEP/ml, Depigoid DUO Grass-Mix/Olea (1000 DPP/ml + 1000 DPP/ml), PLACEBO (Depigoid): the placebo is the solvent used in the investigational medicinal products’ (IMP) formulation. The resulting product is a suspension.

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.

    phase 3 small molecule active

    1 trial

  14. Continuous Gastrocnemius plane block with ropivacaine

    The First People's Hospital of Lianyungang

    Foot Ankle Injuries

    phase 3 small molecule active

    1 trial

  15. Conventional medical treatment

    Lxo Ireland Designated Activity Company

    Coronary Atherosclerosis and Other Heart Disease

    phase 3 small molecule completed

    1 trial

  16. Copiktra 25 mg hard capsules, Copiktra 15 mg hard capsules, DUVELISIB , BENDAMUSTINE , GEMCITABINE

    Secura Bio Limited

    relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype, relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype

    phase 3 small molecule active

    1 trial

  17. Coronary artery bypass grafting

    Rhythm Pharmaceuticals Netherlands B.V.

    Ischemic Heart Failure

    phase 3 other completed

    1 trial

  18. Crenezumab

    Hoffmann-La Roche

    Alzheimer's Disease

    phase 3 small molecule terminated

    1 trial

  19. Cretostimogene Grenadenorepvec

    CG Oncology

    Non Muscle Invasive Bladder Cancer

    phase 3 mab active

    2 trials

  20. Crinecerfont

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    4 trials

  21. Crinecerfont placebo for oral solution, NBI-74788, NBI-74788, Crinecerfont placebo for oral Capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  22. Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  23. Crovalimab

    Hoffmann-La Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  24. Crovalimab, Crovalimab

    Hoffmann-La Roche

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources